Great Bay Bio Exclusively Sponsored 'Intelligent Antibody Development Summit 2025: AI-Powered Innovation' Concludes Successfully in Shanghai

GBB Chief Technology Officer Qi Kai Delivered a Keynote Speech on "Empowering Biopharmaceutical Innovation with Future Intelligent Technologies—Three Stories of Bispecific Antibody Development"The intelligent technology platform of Great Bay Bio (AlfaCell) elaborates on how to address the low expression of TEC antibodies, the need for CMC data when licensing preclinical bispecific antibody molecules to buyers, and the application scenarios where three bispecific antibody candidate PCCs simultaneously enter animal experiments while cell line construction is carried out in parallel, thereby helping clients develop products faster and better.

The AlfaCell platform uses site-specific integration technology to rapidly construct high-yield stable cell lines suitable for industrial-scale production. Its unique "dual-fast" advantage helps customers obtain high-yield cell lines within 1.5 months and quickly predict product quality within 1 month.The platform has achieved excellent case results in the application fields of fusion proteins, monoclonal antibodies, bispecific antibodies, and ADCs. Currently, the AlfaCell platform has assisted customers in obtaining the implied permission for a new drug clinical trial application (IND) from the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), and the first clinical medication has been successfully administered.

▲Great Bay Bio Chief Technology Officer Qi Kai's Speech

GBB (AI) Chief Technology Officer Hongjiang Miao Delivered a Keynote Speech on "Case Study of AI-Driven Design and Development of Antibody Drugs"Introduced how GBB's intelligent technology platform (AlfaDAX) empowers molecular design and optimization of antibody drugs through AI technology, and accelerates preclinical development of antibody drugs using "artificial intelligence + automation."

The AlfaDAX platform uses AI technology to comprehensively evaluate several key factors affecting drug developability, including safety (immunogenicity and toxicity), efficacy (potency and mechanism of action), and developability (physicochemical properties and manufacturability). It intelligently assesses the drug-likeness of molecular compounds and simulates the evaluation and optimization of key druggability characteristics of antibodies.Data shows that the aggregation precipitation prediction accuracy of AlfaDAX antibody druggability analysis is 89%, viscosity prediction accuracy is 96%, and expression prediction accuracy is 86%.Currently, the AlfaDAX system has served multiple biopharmaceutical enterprises.

▲Speech by GBB (AI) Chief Technology Officer Hongjiang Miao

Moreover, Li Song, Vice President of R&D at Immx Biotechnology, shared the technical advantages in the early design, evaluation, and development stages of bispecific antibody drugs; Wu Youling, CEO of MaiLink Bio, discussed the future development prospects and innovations explored during the ADC drug research process; Han Haixiong, Chief Medical Officer of YouLin Pharma, highlighted unique design and execution aspects in the clinical trial phase of ADC drugs; Dai Huazhou, Vice President of Business Development at Xiling Pharmaceutical, shared breakthroughs achieved in diversifying payloads and functional linkers in the innovation process of XDCs; Gong Shiyong, Director of Antibody Engineering at EpimAb Biotherapeutics, presented innovative research results from their TCE bispecific antibody platform in TCE drug development.

▲Guest Speech

Roundtable Discussion

To explore the future development of antibody drugs, this summit held a roundtable discussion themed "A New Horizon: The Path to Next-Generation Antibody Innovation."The moderator of this roundtable is Hua Ye, founder and CEO of BioNova Pharmaceuticals. The participating guests include Dr. Kai Qi, CTO of Great Bay Bio, Qing Li, CEO of Alpha Bright Bio, and Haitao Zhang, Vice President of BD at Jichuan Pharmaceutical.

The roundtable discussion focused on differentiated strategies for antibody drugs at different stages; from an innovative perspective, how to develop drugs with clinical value; how to upgrade the development of next-generation antibody drugs; bottlenecks in the commercialization (BD, market launch, sales) of innovative antibody drugs; and strategies for antibody process development, scale-up, and commercial production.The guests expressed their insights on the innovation path of the next generation of antibodies and affirmed the important role of AI empowerment.

▲ Roundtable Discussion Scene

Wonderful Moments

GBB Utilizes Cutting-Edge Technologies like AI to Empower the Entire Process from Early Drug Discovery to Subsequent Bioprocess Development, Completing the Journey from Target/Antibody Drug Discovery to Early CMC Work within 8 Months. Particularly in the High-Yield Stable Cell Line Development Phase, GBB Achieves a Revolutionary Breakthrough by Obtaining Monoclonal Cells within 1.5 Months and Predicting Product Quality within 1 Month, Which Generated Significant Interest at the Event.

▲ The event site received an enthusiastic response

Schedule Business Consultation

Phone: 400 079 8808

18926497707 (Same number for WeChat)

Email: BD@greatbay-bio.com